Our top pick for
Building a portfolio
MyoKardia, Inc is a biotechnology business based in the US. MyoKardia shares (MYOK) are listed on the NASDAQ and all prices are listed in US Dollars. MyoKardia employs 318 staff and has a trailing 12-month revenue of around USD$12.4 million.
|52-week range||USD$42.65 - USD$225|
|50-day moving average||USD$224.2147|
|200-day moving average||USD$137.4635|
|Wall St. target price||USD$225|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.567|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$12.4 million|
|Gross profit TTM||USD$-226,171,000|
|Return on assets TTM||-23.07%|
|Return on equity TTM||0%|
|Market capitalisation||USD$12 billion|
TTM: trailing 12 months
There are currently 4.6 million MyoKardia shares held short by investors – that's known as MyoKardia's "short interest". This figure is 5.2% down from 4.9 million last month.
There are a few different ways that this level of interest in shorting MyoKardia shares can be evaluated.
MyoKardia's "short interest ratio" (SIR) is the quantity of MyoKardia shares currently shorted divided by the average quantity of MyoKardia shares traded daily (recently around 2.3 million). MyoKardia's SIR currently stands at 2.02. In other words for every 100,000 MyoKardia shares traded daily on the market, roughly 2020 shares are currently held short.
However MyoKardia's short interest can also be evaluated against the total number of MyoKardia shares, or, against the total number of tradable MyoKardia shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case MyoKardia's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 MyoKardia shares in existence, roughly 90 shares are currently held short) or 0.2105% of the tradable shares (for every 100,000 tradable MyoKardia shares, roughly 211 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against MyoKardia.
Find out more about how you can short MyoKardia stock.
We're not expecting MyoKardia to pay a dividend over the next 12 months.
Over the last 12 months, MyoKardia's shares have ranged in value from as little as $42.65 up to $225. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MyoKardia's is 1.8348. This would suggest that MyoKardia's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is Mavacamten, an orally administered allosteric modulator of cardiac myosin, which is in Phase III clinical trial for the treatment of hypertrophic cardiomyopathy (HCM). The company also develops Danicamtiv, an orally administered small molecule, which completed Phase I and Phase IIa clinical trials on patients with dilated cardiomyopathy. Its preclinical programs include MYK-224, a small molecule program for the treatment of HCM targeting hypercontractility and impaired relaxation; ACT-1 for the treatment of diastolic dysfunction; and LUS-1 for the treatment of diastolic dysfunction. Myokardia, Inc. was founded in 2012 and is headquartered in Brisbane, California. As of November 16, 2020, MyoKardia, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.